重组水蛭素Ⅲ的抗凝与抗血栓作用研究

Studies on Anticoagulant and Antithrombotic Effects of Recombinant Hirudin-Ⅲ

目的 研究了自行研制的重组水蛭素Ⅲ在大肠杆菌中的分泌表达产物的抗凝与抗血栓作用。方法 采用大鼠下腔静脉血栓模型和大鼠体外A V循环模型进行水蛭素Ⅲ (HV3)的抗凝及抗血栓作用研究。结果 给予重组水蛭素 2 5 ,5 0 μg/kg两剂量的大鼠下腔静脉血栓重量分别为 2 1.30± 7.35mg和 10 .4 0± 16 .2 0mg ,生理盐水对照组为 5 9.5 0± 4 .95mg ;重组水蛭素 5 0、2 5 μg/kg的血栓湿重为 15 .3± 3.6mg和 2 1.5± 5 .3mg ,生理盐水对照组为 4 8.6± 4 .9mg。结论 重组水蛭素Ⅲ可显著减少静脉血栓重量 ,能显著地降低体外循环的血栓湿重 ,与生理盐水组比较具有很显著的差异 ,结合体外抗凝实验等结果表明 ,重组水蛭素Ⅲ具有很强的体外和体内抗凝抗栓作用 。

AIM The purpose is to study the secretory manufacture of recombinant hirudin Ⅲ(HⅧ) and its anticoagulant and antithrombotic effects. METHODS\ Inferior vena cava thrombosis model in rats and A V circulation \%in vivo\% in rats were used to study recombinant hirudin Ⅲ(HⅧ)′s anticoagulant and antithrombotic effects. RESLUTS\ The weight of inferior vena cava thrombosis was 21.30±7.35 and 10.40±16.20 mg after administrating recombinant hirudin Ⅲ 25 and 50 μg/kg; the weight of thrombosis in A V circulation was 21.5±5.3 mg and 15 3±3.6 mg after administrating recombinant hirudin Ⅲ 25 and 50 μg/kg. CONCLUSION\ The antithrombotic and anticoagulant activity of recombinant hirudin Ⅲ was different from that of placebo group significantly in statistics. It could be developed to make a new antithrombotic drug.